Stockscreener 앱 받기
10.58
0.19%
0.02
시간 외 거래:
10.58
전일 마감가:
$10.56
열려 있는:
$10.64
하루 거래량:
502.12K
Relative Volume:
0.61
시가총액:
$808.83M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-3.6609
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
+7.52%
1개월 성능:
-12.92%
6개월 성능:
-39.85%
1년 성능:
-52.26%
1일 변동 폭
$10.43
$10.78
1주일 범위
$9.44
$10.98
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
10.58 | 807.31M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Is Nurix Therapeutics Inc. trending in predictive chart modelsWeekly Stock Analysis & Weekly Top Gainers Trade List - Newser
Using fundamentals and technicals on Nurix Therapeutics Inc.Market Volume Summary & Community Consensus Stock Picks - Newser
How sentiment analysis helps forecast Nurix Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - Newser
Is Nurix Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
What technical models suggest about Nurix Therapeutics Inc.’s comebackRecession Risk & Safe Entry Point Identification - Newser
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 7.7%What's Next? - MarketBeat
How Nurix Therapeutics Inc. stock performs during market volatilityPortfolio Performance Summary & Low Risk Entry Point Guides - Newser
Sector ETF performance correlation with Nurix Therapeutics Inc.Weekly Trade Recap & High Return Trade Opportunity Guides - Newser
Does Nurix Therapeutics Inc. stock pay reliable dividendsPortfolio Gains Report & Accurate Buy Signal Notifications - Newser
Trend analysis for Nurix Therapeutics Inc. this weekJuly 2025 Highlights & Reliable Entry Point Trade Alerts - Newser
Real time scanner hits for Nurix Therapeutics Inc. explainedEntry Point & Low Risk Entry Point Tips - Newser
Can Nurix Therapeutics Inc. Escape Recent Bear ChannelInvestment Strategy Designed for Capital Protection - beatles.ru
Risks Still Elevated At These Prices As Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Dive 25% - 富途牛牛
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Victory Capital Management Inc. Has $352,000 Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,402 Shares - MarketBeat
Equity Inducement as a Growth Engine: How Nurix Therapeutics Aligns Talent and Shareholder Value in Biotech Innovation - AInvest
What makes Nurix Therapeutics Inc. stock price move sharplyGet exclusive market analysis for investors - Jammu Links News
Is Nurix Therapeutics Inc. stock overvalued or undervaluedUnstoppable investment returns - Jammu Links News
Nurix Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Jammu Links News
Why is Nurix Therapeutics Inc. stock attracting strong analyst attentionHigh-yield portfolio picks - Jammu Links News
How many analysts rate Nurix Therapeutics Inc. as a “Buy”Access high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Nurix Therapeutics Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - Jammu Links News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $51,739.08 in Stock - MarketBeat
What is Nurix Therapeutics Inc. company’s growth strategyCapitalize on emerging investment opportunities - Jammu Links News
What are Nurix Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals for profits - Jammu Links News
Is it the right time to buy Nurix Therapeutics Inc. stockDiscover high-impact investment opportunities - Jammu Links News
Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) PT at $29.31 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.9%Time to Buy? - MarketBeat
When is Nurix Therapeutics Inc. stock expected to show significant growthAdvanced Screener Data Feed To Watch Now - Jammu Links News
Nurix Therapeutics CFO Hans van Houte sells 5402 shares at $11.03 per share. - AInvest
Oppenheimer Reiterates "Outperform" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Y Intercept Hong Kong Ltd Buys Shares of 31,458 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock - MarketBeat
Oppenheimer Reiterates Outperform Rating for Nurix Therapeutics (NRIX) | NRIX Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX) - GuruFocus
Will Nurix Therapeutics Inc. benefit from macro trendsGrowth Focused Entry Plan Suggestions Issued - metal.it
ARK Investment Management LLC Has $18.90 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Real time social sentiment graph for Nurix Therapeutics Inc.Profit Focused Stock Screener Results Released - metal.it
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock By Investing.com - Investing.com Australia
Nurix Therapeutics CFO van Houte sells $51,695 in shares By Investing.com - Investing.com South Africa
Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock - Investing.com
Nurix Therapeutics CFO van Houte sells $51,695 in shares - Investing.com
Will Nurix Therapeutics Inc. Hold Gains Into CloseMulti-Bagger Potential Stock Forecast Tools Released - metal.it
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):